// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

The epidemiology of IBD differs in South Asian migrants compared to Caucasians; results from a systematic review and meta-analysis

R. Misra - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Prediagnostic serum vitamin D levels and risk of inflammatory bowel disease: a pan-European, nested case-control study

J. Opstelten - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Ergocalciferol

Appendectomy is not a treatment option for ulcerative colitis

P. Myrelid - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Change in Crohn's disease behavior in a prospective European population-based inception cohort – the ECCO-EpiCom cohort

J. Burisch - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Increased requirement for steroids, thiopurines and intestinal surgery in Crohn's patients who are smokers at IBD diagnosis; a nationwide population based study

C. Alexakis - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Assessing aCCess to investigations in IBD (ACCID) – results from an international inflammatory bowel disease survey

N.S. Ding - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

What information is available on the internet and social media for faecal microbiota transplantation?

J. Segal - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Impact of migration on IBD incidence in 8 European populations: results from Epicom 2010 inception cohort study

R. Misra - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Elevation in ribosomal and cell cycle gene transcription in macroscopically normal colonic tissue from Icelandic patients with ulcerative colitis

M. Vinayaga-Pavan - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Gene expression differences between Crohn's disease aphthous ulcers and healthy Peyer's patches highlights potential treatment strategies

C. O'Brien - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Response to thiopurines is independent of ATG16L1 genotype

B. Verstockt - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

First analysis from UK IBD Twin Biobank; 16S rRNA gene sequencing identifies reduced diversity in IBD and bacterial taxa associated with disease

J. McDonald - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

The microbiota and it's role in anti-TNF therapy non-response

N.S. Ding - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Microbiota related disease activity and distribution in subgroups of inflammatory bowel disease

P. Ricanek - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Decision-making about emergency and planned stoma surgery for IBD: a qualitative exploration of patient and clinician perspectives

L. Dibley - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Kinship stigma in community-dwelling people with inflammatory bowel disease: family acknowledgement matters

L. Dibley - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Improving care for patients with perianal Crohn's disease; review of a perianal virtual clinic

H. Yarrow - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Accelerated infusions of biosimilar infliximab are safe and well tolerated and monitoring post-infusion is not required

K. Robinson - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Infliximab

Do we need to monitor patients after vedolizumab infusion?

K. Robinson - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Entyvio

The use of a pre-screening tool for anti-TNFs in IBD in four North West NHS trusts: a study

R. Campbell - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved